MS patients displayed lower DNAme levels for MICB compared to controls (Graves et al., 2014; Huynh et al., 2014), in agreement with Abediankenari et al. (2011) and Fernandez-Morera et al. (2008). This evidence concerns the gene MICB and myeloid sarcoma.